ClinicalTrials.gg
CompletedNCT06066528SYNCHRONIZE™-2Updated Aug 6, 2026

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

A Phase 3 interventional study of Survodutide and Placebo in Obesity and Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 143 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
755
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing survodutide in Obesity — 4 open to participants now, 7 under way, 3 of them phase 3. survodutide · Obesity.

Enrollment
2nd of 22
755 · median 121
Started
2023
with 3 others
Phase 3
9 of 22
3 open now
Registered
6th of 22
by date
Lead sponsor
22 of 22
Boehringer Ingelheim

Among the 22 studies testing survodutide in Obesity, this one is the 2nd largest by enrollment, is one of 4 that started in 2023, is one of 9 in phase 3, and was the 6th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing survodutide in Obesity are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About survodutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing survodutide in Obesity, or all of them as a file.
02

Study summary

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate.

The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight.

Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly.

Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff.

The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.

03

Conditions studied

  • Obesity
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥18 years at the time of signing , and at least the legal age of consent in countries where it is >18 years.
  2. (BMI) ≥27 kg/m\^2 at screening.
  3. Diagnosed with Type 2 diabetes mellitus (T2DM) (defined as Glycosylated (HbA1c) ≥6.5% [≥48 mmol/mol]) at least 180 days prior to screening.
  4. HbA1c ≥6.5% (≥48 mmol/mol) and \<10% (\<86 mmol/mol) as measured by the central laboratory at screening.
  5. Currently treated for T2DM with either diet and exercise alone or stable treatment (for at least 3 months prior to screening) per treatment guidelines.
  6. History of at least one self-reported unsuccessful dietary effort to lose body weight Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  1. Body weight change (self-reported) of >5% within 3 months before screening.
  2. Treatment with any medication for the indication obesity within 3 months before screening.
  3. Treatment with any medication for indication of T2DM other than stated in the inclusion criteria and glucagon-like peptide-1 receptor (GLP-1R)-based agonists) and dipeptidyl peptidase 4 inhibitor [DPP-4il).
  4. Known gastric emptying abnormality (e.g., severe diabetic gastroparesis or gastric outlet obstruction).
  5. History of either chronic or acute pancreatitis or elevation of serum lipase or amylase >2x (ULN)) as measured by the central laboratory at screening.
  6. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Further exclusion criteria apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
755 participants (actual)

Study arms

  • Experimental
    Survodutide 3.6 mg

    Combination Product: Survodutide

  • Experimental
    Survodutide 6.0 mg

    Combination Product: Survodutide

  • Placebo comparator
    Placebo

    Combination Product: Placebo

Interventions

  • Combination productSurvodutide

    once weekly subcutaneous injection, pre-filled syringe

    Also known as: BI 456906

  • Combination productPlacebo

    once weekly subcutaneous injection, pre-filled syringe

06

What researchers measure

Primary outcomes

  1. Percentage change in body weight from baseline to Week 76

    Time frame: Baseline and at Week 76

  2. Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76

    Time frame: Baseline and at Week 76

Secondary outcomes

  1. Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 76

    Time frame: Baseline and at Week 76

  2. Achievement of body weight reduction ≥15% (yes/no) from baseline to Week 76

    Time frame: Baseline and at Week 76

  3. Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 76

    Time frame: Baseline and at Week 76

  4. Absolute change from baseline to Week 76 in body weight (kg)

    Time frame: Baseline and at Week 76

  5. Absolute change from baseline to Week 76 in glycosylated haemoglobin A1c (HbA1c) (%)

    Time frame: Baseline and at Week 76

  6. Absolute change from baseline to Week 76 in waist circumference (cm)

    Time frame: Baseline and at Week 76

  7. Absolute change from baseline to Week 76 in systolic blood pressure (SBP) (mmHg)

    Time frame: Baseline and at Week 76

  8. Absolute change from baseline to Week 76 in "Capacity to Resist" domain score of Eating Behaviour patient reported outcome (PRO)

    "Capacity to Resist" domain score of the Eating Behaviour PRO is ranging between 0 and 24 and a higher score indicates a lower capacity to resist.

    Time frame: Baseline and at Week 76

  9. Key secondary endpoint: Absolute change from baseline to Week 76 in Eating Behaviour PRO total score

    Eating Behaviour PRO total score is ranging between 0 and 48 and a higher score indicates a worse eating behaviour (greater desire to eat and/or lower capacity to resist).

    Time frame: Baseline and at Week 76

  10. Absolute change from baseline to Week 76 in body mass index (BMI) (kg/m2)

    Time frame: Baseline and at Week 76

  11. Absolute change from baseline to Week 76 in HbA1c (mmol/mol)

    Time frame: Baseline and at Week 76

  12. Absolute change from baseline to Week 76 in diastolic blood pressure (DBP) (mmHg)

    Time frame: Baseline and at Week 76

  13. Absolute change from baseline to Week 76 in fasting plasma glucose (FPG) (mg/dL)

    Time frame: Baseline and at Week 76

  14. Absolute change from baseline to Week 76 in fasting plasma insulin (FPI) (mIU/L)

    Time frame: Baseline and at Week 76

  15. Absolute change from baseline to Week 76 in total cholesterol (mg/dL)

    Time frame: Baseline and at Week 76

  16. Absolute change from baseline to Week 76 in high density lipoprotein (HDL) cholesterol (mg/dL)

    Time frame: Baseline and at Week 76

  17. Absolute change from baseline to Week 76 in low density lipoprotein (LDL) cholesterol (mg/dL)

    Time frame: Baseline and at Week 76

  18. Absolute change from baseline to Week 76 in very-low-density lipoprotein (VLDL) cholesterol (mg/dL)

    Time frame: Baseline and at Week 76

  19. Absolute change from baseline to Week 76 in triglycerides (mg/dL)

    Time frame: Baseline and at Week 76

  20. Absolute change from baseline to Week 76 in free fatty acids (mg/dL)

    Time frame: Baseline and at Week 76

  21. Absolute change from baseline to Week 76 in alanine aminotransferase (ALT) (U/L)

    Time frame: Baseline and at Week 76

  22. Absolute change from baseline to Week 76 in aspartate aminotransferase (AST) (U/L)

    Time frame: Baseline and at Week 76

07

Study locations

143 sites
  • Pinnacle Research Group, LLC
    Anniston, Alabama 36207, United States
  • EmVenio Research-Atlanta-69582
    Phoenix, Arizona 85032, United States
  • Encompass Clinical Research, Spring Valley
    Spring Valley, California 91978, United States
  • Diablo Clinical Research
    Walnut Creek, California 94598, United States
  • Alliance for Multispecialty Research, LLC - Doral
    Doral, Florida 33172, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • East Coast Institute for Research, LLC - Jacksonville
    Jacksonville, Florida 32216, United States
  • New Horizon Research Center-Miami-69732
    Miami, Florida 33165, United States
  • West Orange Endocrinology
    Ocoee, Florida 34761, United States
  • Emory University
    Atlanta, Georgia 30303, United States
  • East-West Medical Research
    Honolulu, Hawaii 96814, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Evanston Premier Healthcare Research LLC
    Skokie, Illinois 60077, United States
  • Velocity Clinical Research-Valparaiso-68883
    Valparaiso, Indiana 46383, United States
  • Velocity Clinical Research-Sioux City-69728
    Sioux City, Iowa 51106, United States
  • AMR Lexington
    Lexington, Kentucky 40509, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • StudyMetrix Research, LLC
    City of Saint Peters, Missouri 63303, United States
  • Walgreens Clinical Trials-Atlantic City-69647
    Atlantic City, New Jersey 08401, United States
  • Walgreens - Perth Amboy - Site 4544
    Perth Amboy, New Jersey 08861, United States
  • Premier Research, Inc.
    Trenton, New Jersey 08611, United States
  • Velocity Clinical Research - Binghamton
    Binghamton, New York 13905, United States
  • Southgate Medical Group/ Southgate Medical Park
    West Seneca, New York 14224, United States
  • Physicians East, PA
    Greenville, North Carolina 27834, United States
  • Lucas Research, Inc.
    Morehead City, North Carolina 28557, United States
  • Accellacare-Wilmington-67123
    Wilmington, North Carolina 28401, United States
  • EmVenio Research-Oklahoma City-70053
    Oklahoma City, Oklahoma 73139, United States
  • Trial Management Associates
    Myrtle Beach, South Carolina 29572, United States
  • Texas Diabetes and Endocrinology
    Austin, Texas 78731, United States
  • Juno Research, LLC
    Houston, Texas 77040, United States
  • Diabetes & Glandular Disease Clinic, P.A.
    San Antonio, Texas 78229, United States
  • Consano Clinical Research
    Shavano Park, Texas 78231, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
  • Hunter Diabetes Centre
    Merewether, New South Wales 2291, Australia
  • CORE Research Group
    Milton, Queensland 4064, Australia
  • Griffith Health
    Southport, Queensland 4125, Australia
  • Monash University
    Box Hill, Victoria 3128, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Baker Heart and Diabetes Institute
    Melbourne, Victoria 3004, Australia
  • Keogh Institute for Medical Research
    Nedlands, Western Australia 6009, Australia
  • ASZ - Campus Aalst
    Aalst, 9300, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • AZ Delta
    Roeselare, 8800, Belgium
  • Centricity Research (Calgary)
    Calgary, Alberta T2H 2G4, Canada
  • Dr. James Lai
    Vancouver, British Columbia V5Z 4E1, Canada
  • Aggarwal and Associates Ltd.
    Brampton, Ontario L6T 0G1, Canada
  • The Wharton Medical Clinic Clinical Trials Inc.
    Hamilton, Ontario L8L 5G8, Canada
  • Milestone Research Inc.
    London, Ontario N5W 6A2, Canada
  • James Cha, MD
    Oshawa, Ontario L1J 2K1, Canada
  • Stouffville Medical Research Institute Inc.
    Stouffville, Ontario L4A 1H2, Canada
  • Albion Finch Medical Centre
    Toronto, Ontario M9V 4B4, Canada
  • Sameh Fikry Medicine Professional Corporation
    Waterloo, Ontario N2J 1C4, Canada
  • Recherche GCP Research
    Montreal, Quebec H1Y 3H5, Canada
  • Power Clinical Research
    Montreal, Quebec H3M 1L3, Canada
  • Peking University People's Hospital
    Beijing, 100044, China
  • Beijing Pinggu Hospital
    Beijing, 101200, China
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • Changzhou Second People's Hospital
    Changzhou, 213004, China
  • Guangdong Provincial People's Hospital
    Guangzhou, 510080, China
  • Forth Clinical Hospital of Harbin Medical University
    Harbin, 150599, China
  • Huzhou Central Hospital
    Huzhou, 313000, China
  • Center Hospital of Jinan
    Jinan, 250013, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, 471000, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, 210011, China
  • Pingxiang People's Hospital
    Pingxiang, 337000, China
  • Shanghai Municipal Hospital of Traditional Chinese Medicine
    Shanghai, 200071, China
  • Shanghai Fifth People's Hospital affiliated to Fudan University
    Shanghai, 200240, China
  • Siping Central People's Hospital
    Siping, 136000, China
  • Suzhou Municipal Hospital
    Suzhou, 215002, China
  • Tianjin Medical University General Hospital
    Tianjin, 30052, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, 430022, China
  • The First Affiliated Hospital of Xi'an Medical University
    Xi'an, 710077, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, 100029, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, 212013, China
  • Edumed s.r.o
    Broumov, 55001, Czechia
  • NZZ Agentura Science Pro s.r.o., Olomouc
    Olomouc, 772 00, Czechia
  • Dieko, s.r.o.
    Pilsen, 301 00, Czechia
  • Polyclinic Michnova Ltd.
    Prague, 149 00, Czechia
  • Private Practice - Dr. Barbora Diepoltova
    Prague, 190 14, Czechia
  • Sanos Clinic Gandrup (SMO)
    Gandrup, 9362, Denmark
  • HUS, Lihavuustutkimusyksikkö Biomedicum Helsinki
    Helsinki, 00290, Finland
  • Itä-Suomen yliopisto/Health Step Finland Oy
    Kuopio, 70600, Finland
  • CRST - Clinical Research Services Turku
    Turku, 20520, Finland
  • InnoDiab Forschung GmbH
    Essen, 45136, Germany
  • MVZ im Altstadt-Caree Fulda GmbH
    Fulda, 36037, Germany
  • Diabetes Zentrum Hamburg West
    Hamburg, 22607, Germany
  • Institut für Diabetesforschung Münster GmbH
    Münster, 48145, Germany
  • R.E.D. Institut fuer medizinische Studien und Fortbildung GmbH
    Oldenburg in Holstein, 23758, Germany
  • Forschungszentrum Ruhr, KliFo Center GmbH
    Witten, 58455, Germany
  • Athens Medical Center
    Athens, 15125, Greece
  • Thermi Clinic
    Thermi, 57001, Greece
  • Nexthealth S.A
    Thessaloniki, 54645, Greece
  • DRC Drug Research Ltd-Balatonfured-59734
    Balatonfüred, 8230, Hungary
  • Belinus Bt
    Debrecen, 4025, Hungary
  • CRU Hungary Ltd.
    Kistarcsa, 2143, Hungary
  • Arina Trial Research kft.
    Orosháza, 5900, Hungary
  • University of Szeged
    Szeged, 6725, Hungary
  • Fukuhama Chuo Clinic
    Fukuoka, Fukuoka, 810-0066, Japan

Showing the first 100 of 143 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Wharton S, le Roux CW, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, Brueckmann M, Startseva E, Kloer IM, Kaplan LM. Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes Obes Metab. 2026 Feb;28(2):1490-1498. doi: 10.1111/dom.70263. Epub 2025 Nov 11. PubMed 41216778 ↗

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'.For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Dec 2025, 24 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 24 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 4, 2023
StartActual
Nov 27, 2023
Primary completionActual
Dec 12, 2025
CompletionActual
Apr 1, 2026
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06066528
Responsible party
Sponsor
First posted
Oct 4, 2023
Start date
Nov 27, 2023
Primary completion
Dec 12, 2025
Completion
Apr 1, 2026
Last update
Aug 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Survodutide

Start the discussion